Pharmacology, Toxicology and Pharmaceutical Science
Coronavirinae
100%
Pandemic
85%
Infection
85%
SARS Coronavirus
85%
Prevalence
79%
Antiinfective Agent
71%
Observational Study
68%
Diseases
63%
Pharmacotherapy
48%
Prednisolone
46%
Virus Infection
42%
Typical Antipsychotic
42%
Lysine
42%
Skin Infection
42%
Adverse Drug Reaction
42%
Doxycycline
42%
Chronic Obstructive Lung Disease
42%
Antipsychotic
42%
Multiple Sclerosis
42%
Nanoparticle
42%
Randomized Controlled Trial
42%
Comorbidity
42%
Non Small Cell Lung Cancer
42%
COVID-19 Vaccine
42%
Asthma
42%
Cohort Study
42%
Ivermectin
39%
Antibiotics
32%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Anticoagulant Agent
28%
Combination Therapy
19%
Sulfonylurea
14%
Repurposing
14%
Antidiabetic Agent
14%
Calcium Channel Blocker
14%
Drug Dispensing
14%
Diuretics
14%
Antiviral Drug
14%
Risperidone
12%
Aripiprazole
12%
Immunotherapy
12%
Prednisone
12%
Disease
10%
Transdermal
10%
Pseudomonas aeruginosa
10%
Dipeptidyl Carboxypeptidase Inhibitor
10%
Excipient
10%
Clinical Trial
10%
Polypeptide
10%
Angiotensin Receptor Antagonist
10%
Keyphrases
Netherlands
85%
COVID-19
57%
COVID-19 Pandemic
53%
Drug Repurposing
42%
Community Use
42%
Interrupted Time Series
42%
ε-Polylysine
42%
National Institutes of Health
42%
Cancer Drugs
42%
Technology Assessment
42%
Non-small Cell Lung Cancer (NSCLC)
42%
Severe Outcomes
42%
Meta-analysis
42%
Systematic Meta-analysis
42%
Infection Outcome
42%
European Studies
42%
Vaccine Effectiveness
42%
COVID-19 Vaccine
42%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
42%
Adjusted Hazard Ratio
42%
Inception Cohort Study
42%
Older Adults
42%
Treatment Step
42%
Dispensing Pattern
42%
Asthma Treatment
42%
Oral Prednisolone
32%
Ivermectin
28%
Prednisolone
28%
Anticoagulants
28%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
28%
Stringency Index
28%
Corticosteroids
28%
Groningen
24%
Prednisone
21%
Patient-initiated
21%
Primary Series
19%
Pandemic Response
14%
Antidiabetic Drugs
14%
Drug Dispensing
14%
Negatively Associated
14%
Calcium Channel Blockers
14%
Government Restrictions
14%
Prescription Database
14%
Restriction Policy
14%
Clinically Significant
14%
Government Response
14%
Prevalence Rate
14%
Commercial Drugs
14%
Incidence Rate
14%
Sulfonylurea
14%
Medicine and Dentistry
Systematic Review
85%
Infection
85%
Severe Acute Respiratory Syndrome Coronavirus 2
85%
Meta-Analysis
85%
COVID-19
58%
Primary Prevention
42%
Non Small Cell Lung Cancer
42%
COVID-19 Vaccine
42%
Cohort Analysis
42%
Asthma
42%
Omicron Coronavirus Variant
36%
Hazard Ratio
24%
Prednisolone
18%
Observational Study
16%
Targeted Therapy
12%
Immunotherapy
12%
Prednisone
12%
Hydroxychloroquine
10%
ACE Inhibitor
10%
Ivermectin
10%
Clinical Trial
10%
Angiotensin Receptor Antagonist
10%
Health Status
6%
Cancer Therapy
6%
Survival Analysis
6%
Vulnerable Population
6%
Diseases
6%
Intensive Care Unit
6%
Telemedicine
6%
Isoprenaline
6%
Proportional Hazards Model
6%
Drug Repositioning
5%
Intervention Study
5%
Disease
5%
Statin
5%
